预约演示
更新于：2025-11-27
Betaxolol Hydrochloride
盐酸倍他洛尔
更新于：2025-11-27
概要
基本信息
药物类型 小分子化药 |
别名 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol、1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol、Betaxolol + [17] |
作用方式 拮抗剂 |
作用机制 β1-adrenergic receptor拮抗剂(β1-肾上腺素能受体拮抗剂) |
非在研适应症- |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H30ClNO3 |
InChIKeyCHDPSNLJFOQTRK-UHFFFAOYSA-N |
CAS号63659-19-8 |
关联
5
项与 盐酸倍他洛尔 相关的临床试验IRCT20240415061488N1
Evaluation of Betaxolol in improving the Glasgow Outcome Scale Extended (GOSE) of the acute phase of patients with mild to moderate Traumatic Brain Injury: A double blinded randomized Clinical Trial
IRCT20200901048577N1
Comparison of prophylactic effect of Betaxolol 0.5% with Brimonidine 0.2% on IOP elevation after Nd: YAG Laser posterior capsulotomy in patients with posterior capsule opacity
NCT01660620
Topical Betaxolol for the Prevention of Retinopathy of Prematurity
100 项与 盐酸倍他洛尔 相关的临床结果
登录后查看更多信息
100 项与 盐酸倍他洛尔 相关的转化医学
登录后查看更多信息
100 项与 盐酸倍他洛尔 相关的专利（医药）
登录后查看更多信息
1,619
项与 盐酸倍他洛尔 相关的文献（医药）2025-11-02Expert Opinion On Drug Safety
Drug-induced erectile dysfunction: a real-world pharmacovigilance study using the FDA adverse event reporting system database
Article
作者: Zhang, Rui ; Li, Dongxuan ; Du, Qian ; Zhu, Jun ; Wang, Yalan ; Dai, Liyang ; Liu, Songqing ; Wu, Fan ; Zhang, Tongyan
BACKGROUND:
The comprehensive quantitative and comparative risk data of drug-induced erectile dysfunction (ED) are still lacking, and this study aims to supplement this information.
RESEARCH DESIGN AND METHODS:
We reviewed all the ED reports in the FDA Adverse Event Reporting System (FAERS) database from 2004 to 2023 and summarized a potential ED culprit-drug list and its corresponding reporting frequency. The reporting odds ratio (ROR) method was used to conduct disproportionality analysis.
RESULTS:
A total of 20,098 ED reports were retrieved from the FAERS database, which recorded 734 different ED culprit-drugs, involving 74 drug classes. Finasteride was the drug with the highest reporting frequency, and urologicals was the drug class with the highest reporting frequency. In disproportionality analysis, 209 drugs with positive signals showed a close relationship with ED occurrence, among which finasteride was the drug with the highest signal strength. Among 209 drugs with positive signals, 27 were compound preparations, and the risk level of compound preparations was usually higher than their single active ingredient.
CONCLUSIONS:
Our study integrated quantitative and comparative ED risk data of 734 drugs by using the FAERS database, which can provide reference information for regulators, medical personnel, and others involved in drug management and use.
2025-09-01JOURNAL OF CHROMATOGRAPHY A
Cationic separation of medium strong bases by electrophoretic focusing on inverse electromigration dispersion profile. Sensitive analysis of beta-blockers in blood and water with ESI-MS detection
Article
作者: Malá, Zdena ; Gebauer, Petr
Electrophoretic focusing on an inverse electromigration dispersion profile is a method where the migrating profile focuses and separates the analytes and transports them to the detector. Although so far only a few anionic and cationic electrolyte systems have been reported for this technique, it has proved its separation and concentration power and potential for sensitive and selective analyses of samples with complex matrices, typically without any pretreatment. To extend its applicability, there is need for the design of electrolyte systems covering other pH ranges and potential analyte groups. This work describes the first functional cationic system for electrophoretic focusing on inverse electromigration dispersion profile in the alkaline region, based on pentamethylenediamine and acetohydroxamic acid. Computer simulation and experiments have shown that the designed electromigration dispersion profile can be split into smaller sub-profiles to reach increased performance and selectivity. The practical applicability of the system is demonstrated on the analysis of beta-blockers in capillary blood via the dried blood spot technique in combination with electrospray-ionization mass-spectrometric detection. The method allows direct injection of aqueous dried blood spot extracts and sensitive determination of metoprolol and betaxolol in real samples with limits of detection at the 2 nM (500 ngL-1) level. Experiments with direct injection of spiked water samples show that the method can be used also for analysis of beta-blockers in waters with almost the same sensitivity.
2025-08-01COLLOIDS AND SURFACES B-BIOINTERFACES
Enhanced ocular retention and intraocular pressure-lowering efficacy of hydrophobic microspheres for glaucoma treatment
Article
作者: Zhang, Yangrong ; Yu, Xiao ; Rupenthal, Ilva D ; Rui, Wen ; Liu, Li ; Shi, Yihan ; Xiao, Zhenping ; Huang, Ji ; Pan, Bowen ; Pan, Kangyiran ; Huang, Tianying ; Hong, Yuexian ; Long, Qinqiang ; Hou, Dongzhi ; Li, Qinyu ; He, Lin ; Teng, Xifeng
Glaucoma eye drops often suffer from low bioavailability due to rapid drug release and poor ocular retention. This study aimed to address these challenges by developing betaxolol hydrochloride-loaded mesoporous silica polyacrylic resin microspheres (BH@MCM-41 MPs) and comparing their safety, ocular retention, and intraocular pressure (IOP)-lowering efficacy with previously reported betaxolol hydrochloride-loaded montmorillonite polyacrylic resin microspheres (BH@MMT MPs), BH solution, and commercially available Betoptic®. Both BH@MCM-41 MPs and BH@MMT MPs demonstrated sustained drug release over 12 h and good biocompatibility. The impact of physicochemical particle characteristics on micro-interactions with tear film mucins and corneal epithelial cells was investigated. BH@MCM-41 MPs exhibited significantly higher mucin-binding capacity compared to BH@MMT MPs, with approximately double the binding at mucin concentrations over 0.4 mg·mL-1. Rose Bengal assays indicated a more hydrophobic surface for BH@MCM-41 MPs, with a binding constant (K) of 88.51, compared to 69.84 for BH@MMT MPs. In addition, these positively charged microspheres demonstrated prolonged precorneal retention, with BH@MCM-41 MPs achieving 58.17 minutes, compared to 44.49 minutes for BH@MMT MPs. Tear pharmacokinetics further confirmed the extended precorneal residence time of these formulations. Ex vivo corneal permeation studies revealed that the hydrophobic surface of BH@MCM-41 MPs enhanced interaction with corneal epithelial cells, promoting drug release and permeation. The area under the IOP reduction curve (AUC0-36h) for BH@MCM-41 MPs was 1.2-fold greater than for BH@MMT MPs, and significantly higher than for the BH solution and Betoptic. These findings suggest that BH@MCM-41 MPs offer enhanced efficacy for sustained glaucoma treatment through improving precorneal retention.
100 项与 盐酸倍他洛尔 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 中国 | 2000-10-31 | |
| 心绞痛 | 日本 | 1992-10-02 | |
| 原发性高血压 | 日本 | 1992-10-02 | |
| 肾实质性高血压 | 日本 | 1992-10-02 | |
| 开角型青光眼 | 美国 | 1985-08-30 | |
| 高眼压症 | 美国 | 1985-08-30 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 青光眼 | 临床3期 | 美国 | 2003-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 105 | 衊築夢憲襯鹽餘醖鹹襯(鏇壓繭壓願鬱鑰網醖窪) = 範膚範廠糧鬱構鏇齋壓 鹽淵鏇構遞網廠窪衊衊 (蓋築範艱艱壓衊獵鹽窪 ) 更多 | - | 2009-08-01 | |||
Timolol maleate ophthalmic gel-forming solution 0.25% | 衊築夢憲襯鹽餘醖鹹襯(鏇壓繭壓願鬱鑰網醖窪) = 餘獵鏇衊醖願築壓窪壓 鹽淵鏇構遞網廠窪衊衊 (蓋築範艱艱壓衊獵鹽窪 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用